Research Collaborations

 
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers within the U.S. and abroad. These collaborations enable us to develop and validate proprietary tests in a clinical setting with the gained access to robust patient data. CGI’s abundant knowledge in oncology and vast testing capabilities allows for these proprietary tests to be tailored to the collaborators’ needs and specifications. Below is a summary of our active key collaborations.


  • Beth Israel Deaconess Medical Center

    A collaboration between CGI and Beth Israel Deaconess Medical Center was initiated in 2014 to correlate genetic markers to outcomes in patients with Diffuse Large B-cell Lymphoma (DLBCL). The study seeks to assess the relationship of shared genetic variants to overall survival in order to develop a robust model of DLBCL patient survival and outcomes. The company plans to integrate biomarkers validated in the study into CGI’s proprietary tests and genetic signatures for the prediction of outcome in DLBCL.

  • Cleveland Clinic

    CGI and Cleveland Clinic have been collaborating on a renal cell carcinoma diagnostic test focused on validating genomic biomarkers from DNA. CGI received numerous specimens from the Cleveland Clinic. Associated clinical and laboratory data was used for the validation of CGI’s proprietary microarray, UroGenRA®–Kidney. Samples were analyzed in CGI’s clinical laboratory and resulting data has been published and additional data will be published jointly.

  • Columbia University

    CGI entered into a collaboration with leading researchers from Columbia University to identify genomic signatures, biomarkers, and novel treatments for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The collaboration seeks to identify markers to be used in a novel next-generation sequencing (NGS) based panel for the diagnosis and prognosis of MDS and AML, as well as novel therapies to target these diseases.

  • Groupe Hospitalier Pitié Salpétriêre, Paris

    Heterogeneity within kidney cancer specimens is being addressed in a collaboration established with Groupe Hospitalier Pitié Salpétriêre, Paris. The variability of genomic alterations assessed by both array-CGH and NGS will be analyzed in independent samples taken from different segments of tumor samples from the same patients to examine the extent of this phenomenon in this cancer. The impact of site of specimen sampling is of high importance in the clinical diagnostic setting.

  • Huntsman Cancer Institute, University of Utah

    A collaboration has been established with a leading urology clinician to examine and validate genomic biomarkers of response of kidney cancer patients to frontline FDA-approved tyrosine kinase inhibitors. In this collaborative study, CGI is applying both FOCUS::Renal and array-CGH to validate polymorphisms associated with response and determine if within this independent geographically distinct dataset of patients, novel biomarkers of response are identified or the clinical relevance of previously identified prognostic genomic biomarkers are substantiated.

  • Kamineni Hospital

    This focus of this collaboration is to evaluate FHACT®, CGI’s proprietary FISH-based HPV-Associated Cancer Test, as a screening tool for the identification of pre-cancerous and cancerous cervical cells. CGI provides the FHACT® DNA-FISH probe to the collaborating doctor’s laboratory where the assay is performed on Pap smears obtained during routine health visits. The data from this collaboration is analyzed jointly and publications will be jointly produced.

  • Keck Medicine of USC

    In 2014, CGI entered into a collaboration with a leading pathologist from Keck Medicine of the University of Southern California to evaluate the utility of genomics to assist in the diagnosis and prognosis of DLBCL and FL. The collaboration seeks to identify and validate unique gene copy number changes and mutations assessed by NGS that can serve as additional prognostic markers in DLBCL. Furthermore, novel variants are being identified to assist in sub classification of FL that have potential therapeutic and clinical utility.

  • Mayo Clinic

    CGI and Mayo Clinic launched a joint venture, OncoSpire Genomics. The objectives of this venture are to try to discover and validate biomarkers in specific hematologic and urogenital disorders utilizing next-generation sequencing with a possible expansion into other solid tumors, such as esophageal, head and neck, breast and lung cancers. Additionally, the joint venture entity would engage in biomarker discovery utilizing Mayo’s next-generation sequencing facility and the development of commercial products in the form of diagnostic products and services, as well as early stage therapeutic markers.

  • Memorial Sloan-Kettering Cancer Center

    Memorial Sloan-Kettering Cancer Center and CGI are engaged in several collaborations across multiple cancer categories. Current collaborative efforts are focused on kidney cancer where projects are investigating multiple aspects of the care of these patients, from improvement of diagnostic and prognostic utility of core needle biopsy genomic analyses by array-CGH and NGS, to evaluation of genomic alterations associated with metastasis, site of metastasis, to prognostic markers of response of patients to frontline therapeutic agents.

  • Moffitt Cancer Center

    CGI entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center.  The studies will examine a number of genetic variants as predictors for the most common side effects associated with chemotherapy treatment.  A second collaboration will examine the role of individual genetic variants in the effectiveness of pain control in cancer. Through these studies, genetic biomarkers found to have clinical significance in predicting CINV and effectiveness of pain control in patients will be integrated into the company’s comprehensive pharmacogenomics panels. These panels will allow clinical trials investigators and oncologists to better tailor treatments to reduce CINV-related side effects. CGI plans on launching a comprehensive next-generation sequencing based panel focused on pharmacogenomics later this year.

  • National Cancer Institute

    The collaboration with NCI was formed to interrogate the potential role of identification of host genomic abnormalities by FISH (Fluorescence in situ hybridization) as a screening tool for the detection of HPV-associated pre-cancerous cells and cancerous cells. NCI provided liquid biopsy specimens for analysis by FHACT™, CGI’s proprietary FISH-based HPV-Associated Cancer Test. The NCI also provided anal liquid biopsy specimens that will be used for the evaluation of FHACT™ in anal cancer.

  • North Shore-Long Island Jewish Health System

    Leading clinicians and scientists from North Shore LIJ have provided a significant quantity of clinical specimens in a study of chronic lymphocytic leukemia (CLL) that were used for the clinical validation of CGI’s proprietary microarray, MatBA® -CLL. CGI analyzed these samples in-house and published the resulting data jointly. CGI will use the same samples for additional collaborative studies involving the search for additional molecular biomarkers of CLL.

  • University of Alabama School of Medicine

    CGI and the University of Alabama School of Medicine entered into a collaboration to investigate biomarkers for primary central nervous system lymphomas (PCNSL). PCNSL is a group of poorly understood, aggressive cancers. The collaboration leverages CGI’s proprietary array-CGH technique to investigate chromosomal changes in PCNSL.

  • University of Iowa Cancer Center

    CGI and the University of Iowa are involved in the validation of the DLBCL microarray. Data from these studies have been published and more studies are ongoing.

  • Kamineni Hospital

    This focus of this collaboration is to evaluate FHACT®, CGI’s proprietary FISH-based HPV-Associated Cancer Test, as a screening tool for the identification of pre-cancerous and cancerous cervical cells. CGI provides the FHACT® DNA-FISH probe to the collaborating doctor’s laboratory where the assay is performed on Pap smears obtained during routine health visits. The data from this collaboration is analyzed jointly and publications will be jointly produced.

  • National Cancer Institute

    The collaboration with NCI was formed to interrogate the potential role of identification of host genomic abnormalities by FISH (Fluorescence in situ hybridization) as a screening tool for the detection of HPV-associated pre-cancerous cells and cancerous cells. NCI provided liquid biopsy specimens for analysis by FHACT™, CGI’s proprietary FISH-based HPV-Associated Cancer Test. The NCI also provided anal liquid biopsy specimens that will be used for the evaluation of FHACT™ in anal cancer.

  • Cleveland Clinic

    CGI and Cleveland Clinic have been collaborating on a renal cell carcinoma diagnostic test focused on validating genomic biomarkers from DNA. CGI received numerous specimens from the Cleveland Clinic. Associated clinical and laboratory data was used for the validation of CGI’s proprietary microarray, UroGenRA®–Kidney. Samples were analyzed in CGI’s clinical laboratory and resulting data has been published and additional data will be published jointly.

  • Groupe Hospitalier Pitié Salpétriêre, Paris

    Heterogeneity within kidney cancer specimens is being addressed in a collaboration established with Groupe Hospitalier Pitié Salpétriêre, Paris. The variability of genomic alterations assessed by both array-CGH and NGS will be analyzed in independent samples taken from different segments of tumor samples from the same patients to examine the extent of this phenomenon in this cancer. The impact of site of specimen sampling is of high importance in the clinical diagnostic setting.

  • Huntsman Cancer Institute, University of Utah

    A collaboration has been established with a leading urology clinician to examine and validate genomic biomarkers of response of kidney cancer patients to frontline FDA-approved tyrosine kinase inhibitors. In this collaborative study, CGI is applying both FOCUS::Renal and array-CGH to validate polymorphisms associated with response and determine if within this independent geographically distinct dataset of patients, novel biomarkers of response are identified or the clinical relevance of previously identified prognostic genomic biomarkers are substantiated.

  • Memorial Sloan-Kettering Cancer Center

    Memorial Sloan-Kettering Cancer Center and CGI are engaged in several collaborations across multiple cancer categories. Current collaborative efforts are focused on kidney cancer where projects are investigating multiple aspects of the care of these patients, from improvement of diagnostic and prognostic utility of core needle biopsy genomic analyses by array-CGH and NGS, to evaluation of genomic alterations associated with metastasis, site of metastasis, to prognostic markers of response of patients to frontline therapeutic agents.

  • Columbia University

    CGI entered into a collaboration with leading researchers from Columbia University to identify genomic signatures, biomarkers, and novel treatments for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The collaboration seeks to identify markers to be used in a novel next-generation sequencing (NGS) based panel for the diagnosis and prognosis of MDS and AML, as well as novel therapies to target these diseases.

  • North Shore-Long Island Jewish Health System

    Leading clinicians and scientists from North Shore LIJ have provided a significant quantity of clinical specimens in a study of chronic lymphocytic leukemia (CLL) that were used for the clinical validation of CGI’s proprietary microarray, MatBA® -CLL. CGI analyzed these samples in-house and published the resulting data jointly. CGI will use the same samples for additional collaborative studies involving the search for additional molecular biomarkers of CLL.

  • Beth Israel Deaconess Medical Center

    A collaboration between CGI and Beth Israel Deaconess Medical Center was initiated in 2014 to correlate genetic markers to outcomes in patients with Diffuse Large B-cell Lymphoma (DLBCL). The study seeks to assess the relationship of shared genetic variants to overall survival in order to develop a robust model of DLBCL patient survival and outcomes. The company plans to integrate biomarkers validated in the study into CGI’s proprietary tests and genetic signatures for the prediction of outcome in DLBCL.

  • Keck Medicine of USC

    In 2014, CGI entered into a collaboration with a leading pathologist from Keck Medicine of the University of Southern California to evaluate the utility of genomics to assist in the diagnosis and prognosis of DLBCL and FL. The collaboration seeks to identify and validate unique gene copy number changes and mutations assessed by NGS that can serve as additional prognostic markers in DLBCL. Furthermore, novel variants are being identified to assist in sub classification of FL that have potential therapeutic and clinical utility.

  • University of Alabama School of Medicine

    CGI and the University of Alabama School of Medicine entered into a collaboration to investigate biomarkers for primary central nervous system lymphomas (PCNSL). PCNSL is a group of poorly understood, aggressive cancers. The collaboration leverages CGI’s proprietary array-CGH technique to investigate chromosomal changes in PCNSL.

  • University of Iowa Cancer Center

    CGI and the University of Iowa are involved in the validation of the DLBCL microarray. Data from these studies have been published and more studies are ongoing.

  • Columbia University

    CGI entered into a collaboration with leading researchers from Columbia University to identify genomic signatures, biomarkers, and novel treatments for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The collaboration seeks to identify markers to be used in a novel next-generation sequencing (NGS) based panel for the diagnosis and prognosis of MDS and AML, as well as novel therapies to target these diseases.

  • Mayo Clinic

    CGI and Mayo Clinic launched a joint venture, OncoSpire Genomics. The objectives of this venture are to try to discover and validate biomarkers in specific hematologic and urogenital disorders utilizing next-generation sequencing with a possible expansion into other solid tumors, such as esophageal, head and neck, breast and lung cancers. Additionally, the joint venture entity would engage in biomarker discovery utilizing Mayo’s next-generation sequencing facility and the development of commercial products in the form of diagnostic products and services, as well as early stage therapeutic markers.

  • Moffitt Cancer Center

    CGI entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center.  The studies will examine a number of genetic variants as predictors for the most common side effects associated with chemotherapy treatment.  A second collaboration will examine the role of individual genetic variants in the effectiveness of pain control in cancer. Through these studies, genetic biomarkers found to have clinical significance in predicting CINV and effectiveness of pain control in patients will be integrated into the company’s comprehensive pharmacogenomics panels. These panels will allow clinical trials investigators and oncologists to better tailor treatments to reduce CINV-related side effects. CGI plans on launching a comprehensive next-generation sequencing based panel focused on pharmacogenomics later this year.